Metabolic therapeutics in angina pectoris: History revisited with perhexiline
- Publication Type:
- Journal Article
- Citation:
- European Journal of Cardiovascular Nursing, 2006, 5 (2), pp. 175 - 184
- Issue Date:
- 2006-06-01
Closed Access
| Filename | Description | Size | |||
|---|---|---|---|---|---|
| 2010005879OK.pdf | 167.49 kB |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
The ever-increasing burden of ischaemic heart disease and its common manifestation chronic angina pectoris calls for the exploration of other treatment options for those patients who despite the maximum conventional pharmacological and surgical interventions continue to suffer. Such exploration has led to the increasing use of new metabolically acting antianginal agents and the re-emergence of an old and somewhat forgotten pharmacological agent, perhexiline maleate. This review aims to update the cardiac nurse with knowledge to manage the care a patient receiving perhexiline maleate treatment and provide a brief review of three new metabolic agents: trimetazidine, ranolazine and etomoxir. © 2006 European Society of Cardiology.
Please use this identifier to cite or link to this item: